421
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 23, 2022Completed
Stage III Multiple Myeloma: 437 Clinical Trials, Page 43 of 44
Hide Studies Not Open or Pending
422
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 3, 2023Recruiting
423
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:November 20, 2019Completed
424
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition(s):Plasma Cell MyelomaLast Updated:January 4, 2023Active, not recruiting
425
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:August 15, 2013Completed
426
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition(s):Multiple MyelomaLast Updated:January 4, 2023Completed
427
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:August 29, 2013Completed
428
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Condition(s):Multiple Myeloma; Lymphocytic Leukemia, Chronic; Lymphoma, Low-GradeLast Updated:March 8, 2017Completed
429
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:June 15, 2021Recruiting
430
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 17, 2020Completed